IP Library Patent Application 12274089
Patent Application
App. No. 12/274,089

USE OF BUCKYSOME OR CARBON NANOTUBE FOR DRUG DELIVERY

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/274,089
Abstract

Compositions and methods for administering a therapeutic agent to a mammal are disclosed. The compositions comprise either (i) vesicles comprising an amphiphilic substituted fullerene, wherein the therapeutic agent is present in the vesicle interior or between layers of the vesicle wall, (ii) a substituted fullerene, comprising a fullerene core and a functional moiety, wherein the therapeutic agent is associated with the substituted fullerene, or (iii) carbon nanotubes, wherein the therapeutic agent is covalently bonded to the carbon nanotubes.

Claims (18)

1 - 16 . (canceled)

17 . A composition, comprising:

a fullerene core;

a covalent linker linking the fullerene core to a steroid; and

the steroid.

18 . The composition of claim 17 , wherein the fullerene core is selected from the group consisting of C 60 and C 70 .

19 . The composition of claim 17 , wherein the covalent linker is an ester.

20 . The composition of claim 17 , wherein the covalent linker is bonded to the fullerene core by a process selected from the group consisting of a 1,3-dipolar addition, a Diels-Alder reaction, a cycloaddition process, a cyclopropanation by addition/elimination, and an addition of a carbanion/alkyl lithium/Grignard reagent.

21 . The composition of claim 17 , wherein the covalent linker is bonded to the fullerene core by a 1,3-dipolar addition.

22 . A composition, comprising:

a fullerene core;

a substituent bonded to the fullerene core;

a covalent linker linking the substituent to a steroid; and

the steroid.

23 . The composition of claim 22 , wherein the fullerene core is selected from the group consisting of C 60 and C 70 .

24 . The composition of claim 22 , wherein the covalent linker is an ester.

25 . The composition of claim 22 , wherein the substituent is bonded to the fullerene core by a process selected from the group consisting of a 1,3-dipolar addition, a Diels-Alder reaction, a cycloaddition process, a cyclopropanation by addition/elimination, and an addition of a carbanion/alkyl lithium/Grignard reagent.

26 . The composition of claim 25 , wherein the substituent is bonded to the fullerene core by a 1,3-dipolar addition.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Feb 6, 2015
From: HANSEN MEDICAL, INC.
To: LUNA INNOVATIONS INCORPORATED
Reel/Frame 034914/0407 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2010
From: TEGO BIOSCIENCES CORPORATION
To: LUNA INNOVATIONS INCORPORATED
Reel/Frame 024526/0970 →
SECURITY AGREEMENT Recorded Feb 25, 2010
From: LUNA INNOVATIONS INCORPORATED
To: SILICON VALLEY BANK
Reel/Frame 023985/0718 →
SECURITY AGREEMENT Recorded Jan 14, 2010
From: LUNA INNOVATIONS INCORPORATED
To: HANSEN MEDICAL, INC.
Reel/Frame 023792/0388 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 11, 2008
From: HIRSCH, ANDREAS; SAGMAN, URI; WILSON, STEPHEN R.
To: C SIXTY INC.
Reel/Frame 021961/0458 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 11, 2008
From: C SIXTY, INC.
To: C SIXTY ACQUISITION CORPORATION
Reel/Frame 021961/0532 →
CHANGE OF NAME Recorded Dec 11, 2008
From: C SIXTY ACQUISITION CORPORATION
To: TEGO BIOSCIENCES CORPORATION
Reel/Frame 021961/0679 →